Trial Profile
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Capecitabine; Eribulin; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms OlympiAD
- Sponsors AstraZeneca; AstraZeneca AB
- 20 Dec 2023 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 09 Oct 2023 Planned End Date changed from 29 Sep 2023 to 29 Dec 2023.
- 05 Jul 2023 Planned End Date changed from 29 Dec 2023 to 29 Sep 2023.